Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
about
Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivityNonsteroidal anti-inflammatory drugs in systemic lupus erythematosusOral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.Management of cardiovascular complications in systemic lupus erythematosus.An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.Practical issues in the treatment of patients with heart failure.Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugsPreventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies.Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.Cyclooxygenase-2 inhibitors: promise or peril?The effect of β-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis.Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.Comparing the efficacy of NSAIDs and paracetamol in children.Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.Vitex negundo inhibits cyclooxygenase-2 inflammatory cytokine-mediated inflammation on carrageenan-induced rat hind paw edemaComparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update.Selective COX-2 Inhibitor (Meloxicam) and Tooth-Supporting Bone Quality. A Histomorphometric Study in Rats.Elevation of antidermatophytic action of mefenamic acid by cobalt ions.Central effects of acetylsalicylic acid on trigeminal-nociceptive stimuliCyclo-oxygenase-1 inhibition increases acid secretion by modulating H+,K+-ATPase expression and activation in rabbit parietal cells.Treating acute gouty arthritis with selective COX 2 inhibitors.Investigation of anti-dermatophytic effects of non-steroidal anti-inflammatory drugs on trichophyton mentagrophytes and epidermophyton floccosum.Celecoxib and ankylosing spondylitis.Gastric acid is the key modulator in the pathogenesis of non-steroidal anti-inflammatory drug-induced ulceration in rats.Possible celecoxib-induced gastroduodenal ulceration.Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia.Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity.Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.Beneficial pharmacological effects of levosimendan on antioxidant status of acute inflammation induced in paw of rat: involvement in inflammatory mediators.Effects of cyclooxygenase-2 inhibitor on glucagon-induced delayed gastric emptying and gastric dysrhythmia in dogs.Development of NSAIDs prescription indicators based on health outcomes.
P2860
Q28165861-D2FA8291-7E82-4151-91E5-C8A15D6E9A9BQ28182127-6B5A8F6D-3160-44B7-9435-56A9ED9515CEQ31106519-A70C803F-FFEF-4DCF-9263-BD129D339FE5Q33730536-D3D1C485-7B0A-405D-9D51-58428AFFC376Q33952311-1F5AB9B1-0254-47F1-997A-DAB6D786A478Q34088218-8483419A-615F-4D67-95BC-767E3F11C799Q34093824-843DD5D4-C611-4183-8B4C-B25B50F1E421Q34267128-1DEDD46B-950C-43D9-BCA8-57219A500A01Q34536718-22C2C423-CDC4-4FF9-8DD1-A109D8063285Q34954633-634A5EFF-20C4-4D89-96D1-1169F3193573Q35017693-7DFA7FE6-AFE7-42AD-B53C-FBDC2F3463ACQ35148963-BE352CE7-363B-4C4D-90A1-CB713E8CB6A6Q35196870-C9C86550-F8D7-4AB5-B120-E758863B0B79Q35680419-0229FAD8-50FE-4853-8933-0B3D6C439176Q35827826-7DBC0DCF-EB96-47BE-B5E1-8FAF43ED925CQ36180903-A8034B7A-236C-4A9C-8F72-D678C931F3EDQ36349740-05F168FF-A3FB-4B64-A675-A07C471277F8Q37709435-F79A8109-44DC-42AF-AE1E-1CD600C47E07Q38792812-92CDEFCD-2D9D-495B-BE59-5D5A38A40277Q41523741-E2ECFCC4-DDB1-4021-8ED2-F0CE35A5C7C4Q42095388-72FC15A1-9049-48C6-BF4B-FADC4A2E3550Q42441036-CD9DCD75-DD60-4D96-AB1C-21552F60769AQ42780423-66858014-8E45-4F25-A750-D285BA8BF981Q42927897-DF9765A1-456A-4A9B-BC8A-74A200D71D38Q43061712-362F286A-F2B4-4022-873A-2D605E2B913BQ43191151-22B19D9D-F174-49CF-95FA-7BE08F1B22DEQ43642338-AFC2180B-ABFB-4151-8BBE-8BB66878D068Q44975072-0722C0FB-C8AA-4994-BE08-B4C221C34D07Q45125345-370FC997-264A-479B-840B-EA5719B42BC3Q45188543-4CE4BBAA-5CCA-4FCE-9F5D-D98D1CAEC694Q46664771-F08BF1F0-1765-4770-B0B5-BAAEC9DF2CE1Q50058507-F5DF718A-7819-4330-B0C9-311D4FC2D674Q50708055-7FAF43ED-94F2-45C9-A9F9-E5D3A6E3300BQ51699918-AEDDBFFB-6D2D-484D-B0D2-997D69B1017B
P2860
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@ast
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@en
type
label
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@ast
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@en
prefLabel
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@ast
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@en
P1476
Do cyclooxygenase-2 inhibitors ...... ess gastrointestinal toxicity?
@en
P2093
P304
P356
10.7326/0003-4819-132-2-200001180-00008
P407
P577
2000-01-01T00:00:00Z